Edesa Biotech (EDSA)
NASDAQ:EDSA
Want to see EDSA full AI Analyst Report?
EDSA Stock Chart & Stats
$1.48
>-$0.01(-0.02%)
At close: 4:00 PM EST
$1.48
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$0.72 - $9.37
Previous CloseN/A
Volume1.31K
Average Volume (3M)2.17M
Market Cap
$44.75M
Enterprise Value$37.45M
Total Cash (Recent Filing)$12.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.78
Next Earnings
May 08, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding8,348,161
10 Day Avg. Volume217,580
30 Day Avg. Volume2,166,643
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-368.55
Enterprise Value/Ebitda-4.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 EfficacyRobust Phase 3 mortality reduction that’s consistent across severity groups materially de-risks the lead program. Durable clinical efficacy improves regulatory and payer negotiation leverage, raises probability of approval/label expansion and strengthens partner/licensing dynamics long-term.
Conservative Balance SheetMinimal leverage and a materially strengthened equity base reduce solvency and interest-service risk during lengthy development. This financial flexibility preserves operational optionality, supports clinical execution, and limits forced distressed financing over the medium term.
IP And Scale-up ReadinessProvisional patent filings plus manufacturing scale-up and government-funded trial support create structural advantages: protectability, manufacturing readiness, and potential external funding/partnerships. These build commercial-readiness and raise barriers to entry ahead of launch.
Bears Say
No Commercial RevenueLack of product revenues means the company cannot self-fund development or demonstrate commercial execution, leaving long-term viability contingent on pipeline transitions to approval and market uptake. This structural gap prolongs funding dependence and strategic uncertainty.
Sustained Cash BurnPersistent negative operating and free cash flow steadily consumes cash reserves and narrows runway. Continued burn forces recurring financing or milestone-dependent inflows, increasing dilution risk and potentially delaying or constraining development and commercialization timelines.
Reliance On External CapitalDependence on equity and occasional non‑operating financing exposes strategy to capital market cycles and dilution. Structural reliance on raises can hinder long-term planning, limit negotiation leverage with partners, and create execution risk if access to financing tightens.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was $0.72 and its highest was $9.37 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is $44.75M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is May 08, 2026 which is in 20 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on Feb 13, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.525 by $0.245.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Overvalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.26.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 8,348,161 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.525. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
EDSA Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $232.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.65%
12-Months-Change
Fundamentals
Return on Equity
-55.75%
Trailing 12-Months
Asset Growth
253.26%
Trailing 12-Months
Company Description
Edesa Biotech
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
18.86% Insiders
0.90% Mutual Funds
34.60% Other Institutional Investors
45.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---